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http://dx.doi.org/10.1016/j.jfma.201
0929-6646/Copyright ª 2015, ElsevierThere are great diversities of clinical phenotypes among the various familial Alzheimer’s dis-
ease (FAD) families. We aimed to systematically review all the previously reported cases of
FAD and to perform comparisons between Asian and white patients. In this regard, we
collected individual-level data from 658 pedigrees. We found that patients with presenilin 1
(PSEN1) mutations had the earliest age of onset (AOO; 43.3  8.6 years, p < 0.001) and were
more commonly affected by seizures, spastic paraparesis, myoclonus, and cerebellar signs
(p < 0.001, p < 0.001, pZ 0.003, and pZ 0.002, respectively). Patients with PSEN2 mutations
have a delayed AOO with longest disease duration and presented more frequently with disori-
entation (pZ 0.03). Patients with amyloid precursor protein (APP) mutations presented more
frequently with aggression (p Z 0.02) and those with APP duplication presented more
frequently with apraxia (pZ 0.03). PSEN1mutations before codon 200 had an earlier AOO than
those having mutations after codon 200 (41.4  8.0 years vs. 44.7  8.7 years, p < 0.001).
Because 42.9% of the mutations reported are novel, the mutation spectrum and clinicalave no conflicts of interest relevant to this article.
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68 Y.-F. Shea et al.features in Asian FAD families could be different from that of whites. Asian patients with PSEN1
mutations presented more frequently with disorientation (p Z 0.02) and personality change
(p Z 0.01) but less frequently with atypical clinical features. Asian patients with APP muta-
tions presented less frequently with aphasia (pZ 0.02). Thus, clinical features could be modi-
fied by underlying mutations, and Asian FAD patients may have different clinical features when
compared with whites.
Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Alzheimer’s disease (AD) usually has sporadic occurrence,
with age of onset (AOO) in most cases being 65 years and
older. Autosomal dominant familial AD (FAD) accounts for
0.5% of all AD cases and usually presents before the age of
65 years in individuals with a positive family history in at
least three generations.1 Approximately 50% of the FAD
patients carry mutations in one of the three genes, namely,
presenilin 1 (PSEN1), PSEN2, and amyloid precursor protein
(APP).1 In these patients, > 230 mutations have been
identified in one of these three genes.2,3 These mutations
increase the production of amyloid beta 42, which results in
the younger age of FAD onset.1 Identification of FAD is of
paramount importance as the family should be offered
genetic counseling. In addition, identification of underlying
mutations enhances our knowledge about the pathogenesis
of AD and most importantly, the asymptomatic carriers of
mutations can be ideal candidates for future clinical trials
of disease-modifying treatment for AD.
Given the diversities of reported clinical phenotypes
among the various FAD families with different mutations, it
is important to perform a systematic review of the previ-
ously reported FAD families to study the variations in clin-
ical phenotypes and genotypes and to increase the
awareness of FAD to allow for accurate diagnosis of more
FAD families. There has only been one comprehensive sys-
tematic review on AOO and disease course of FAD4 and two
systematic reviews on PSEN2 mutations.5,6 However, there
has been no comprehensive systematic review on clinical
characteristics of FAD patients having mutations in all three
genes or any comparison between different ethnicities.
There might be differences in clinical features between
Asian and white FAD patients because of ethnic differences
or differences in the location of mutations. Therefore, our
objective is to systematically review all the reported cases
of FAD worldwide and compare the clinical characteristics
according to the mutated genes, position of mutations for
PSEN1, and ethnicity (particularly between Asians and
whites).Methods
Data sources and study selection
We searched through Alzheimer’s disease/Frontotemporal
Dementia Mutation Database (AD&FTDMDB), the Alzheimer
Research Forum Database (ALZFORUM), PubMed, and theChina Knowledge Resource Integrated Database KNS, be-
tween February 1, 1991, and January 31, 2015, using the
following keywords: “early onset Alzheimer’s disease,”
“autosomal dominant Alzheimer’s disease,” “familial Alz-
heimer’s disease,” “presenilin,” “PSEN1,” “PSEN2,” and
“APP”. The articles retrieved were further screened to
identify additional articles satisfying the inclusion criteria.
The articles were evaluated individually according to the
following inclusion criteria: (1) reporting the clinical fea-
tures of autosomal dominant FAD in humans carrying PSEN1,
PSEN2, and APP mutations or APP duplications, (2)
describing those mutations with possible or proven patho-
genicity as defined by the algorithm proposed by Guerreiro
et al,7 ALZFORUM,2 and AD&FTDMDB3; and (3) written in
either English or Chinese. Studies describing nonpathogenic
PSEN1, PSEN2, or APP mutations were excluded from this
study.
Study selection and appraisal of the studies were per-
formed independently by two authors (Y.-F.S. and L.-
W.C.). Disagreement was resolved by consensus. To avoid
potential double reporting, pedigrees for each mutation
type were manually examined for possible duplicates and
these were removed where identified. We have included
an unreported pedigree with p.His163Arg missense muta-
tion of PSEN1 diagnosed in Hong Kong, including two
affected family members: a female patient with AOO at
42 years and a male patient with AOO at 41 years. The
combined dataset contains 658 pedigrees, 1890 in-
dividuals, of whom 790 were affected by FAD with known
AOO7e94 (please refer to supplementary materials online
for a full list of references included). From each of the
study, clinical features of the patients were extracted.
Asymptomatic mutation carriers were not considered. The
following information was extracted if available: socio-
demographic characteristics (age, sex, and ethnicity),
clinical features (AOO, age of death, disease duration,
initial cognitive disturbances, initial neuropsychiatric
symptoms, atypical manifestations, and neurological ex-
amination), types of mutation, apolipoprotein E (APOE)
status, and initial Mini-Mental State Examination (MMSE)
scores. AOO refers to the age of onset of progressive
cognitive symptoms as determined by investigators rather
than the age at which the individual received a clinical
diagnosis of dementia or mild cognitive impairment.
“Disease course in years” was calculated by the difference
between the AOO and the known age at death. Clinical
data from whites (including Europeans and non-African
Americans, n Z 871) were extracted and compared with
those of Asians (n Z 137).
Review of familial Alzheimer’s disease 69Statistical analysis
Statistical analyses were performed using one-way analysis
of variance or KruskaleWallis test for continuous variables
and Chi-square test for categorical variables. A correlation
analyses between the AOO and disease duration was per-
formed by Spearman correlation. All analyses were per-
formed using SPSS version 18.0 (SPSS Inc., Chicago, IL,
USA). A p value  0.05 was considered statistically
significant.Results
Overall worldwide data
The characteristics of the patients included are summa-
rized in Table 1. The number of patients suffering from
mutations in PSEN1 and PSEN2 and in APP and APP dupli-
cation were 1444 (76.4%), 78 (4.1%), 287 (15.2%), and 81
(4.3%), respectively. Information on AOO, age of death,
sex, APOE status, and presenting MMSE score was available
in 790 (41.8%), 318 (16.8%), 558 (29.5%), 459 (24.3%), and
167 (8.8%) patients, respectively. The total number of
mutations included in this review for PSEN1. PSEN2, and
APP (including duplication) were 220, 19, and 28, respec-
tively (see Table S1 in the supplementary material online
for each of the mutations in our dataset).
Table 2 summarizes the AOO, sex distribution, present-
ing MMSE score, age of death, and disease duration for
patients with mutations in PSEN1 and PSEN2 and in APP and
APP duplications. Patients with PSEN1 mutations had the
lowest AOO and age of death (mean 43.3  8.6 years andTable 1 Summary of basic characteristics of patients
included.
Baseline characteristics Findings
Total No. of pedigrees included 658
Total No. of patients 1890
Total No. of publications 262
Information on clinical features
available
469
Age of onset (y) 45.6  9.4 (N Z 790)
No. of female patients 318 (57.0) (N Z 558)
MMSE at presentation 16  7.3 (N Z 167)
Age of death (y) 53.6  10.9
(N Z 318)
Disease duration (y) 9.2  4.7 (N Z 336)
Apolipoprotein E status (N Z 459)
ε2ε2 0
ε2ε3 22 (4.8)
ε2ε4 12 (2.6)
ε3ε3 311 (67.8)
ε3ε4 102 (22.2)
ε4ε4 12 (2.6)
Data are presented as %, n (%) or mean  SD, unless otherwise
indicated.
MMSE Z Mini-Mental State Examination; SD Z standard
deviation.50.5  9.7 years, respectively; p < 0.001) and patients with
PSEN2 mutations had the oldest AOO and age of death
(mean 58.1  9.5 years and 71.8  10.6 years, respectively;
p < 0.001). Patients with PSEN2 mutations had the longest
disease duration [median 11 years, interquartile range
(IQR) 10e15 years; p Z 0.03]. There was a higher propor-
tion of women with mutations in APP, compared with other
gene mutations (p Z 0.018). The AOO of disease did not
correlate with the duration of disease before death
(p Z NS). The APOE status did not affect the age of pre-
sentation, age of death, or duration of clinical course of the
disease irrespective of whether we included all the patients
or calculated it according to individual mutated genes (i.e.,
PSEN1, PSEN2, and APP mutations and APP duplications;
data not shown).
Table 3 summarizes the initial cognitive symptoms,
neuropsychiatric symptoms, and atypical clinical features
of patients with PSEN1, PSEN2, or APP mutations and APP
duplication. The PSEN2 mutations presented more
commonly with disorientation (p Z 0.03); APP mutations
presented more commonly with aggression (pZ 0.02); APP
duplication presented more commonly with apraxia
(p Z 0.03). With regard to the atypical clinical features
along the clinical course, patients with PSEN1 mutations
were more likely to be affected by atypical clinical features
including seizures (p < 0.001), spastic paraparesis
(p < 0.001), myoclonus (p Z 0.003), and cerebellar fea-
tures (p Z 0.002).
Table 4 presents a comparison of clinical characteristics
between patients with PSEN1 mutations before and after
codon 200. Patients with PSEN1mutations before codon 200
(n Z 227) have an earlier AOO than those after codon 200
(nZ 337; 41.4  8.0 years vs. 44.7  8.7 years, p < 0 .001),
but there was no difference in the total disease duration
before death (p Z 0.15). Patients with PSEN1 mutations
before codon 200 were more likely to be affected by sei-
zures (36.9% vs. 23.1%, pZ 0.01) and myoclonus (42.7% vs.
21.6%, p < 0.001) along their clinical course than those with
mutations after codon 200. Patients with PSEN1 mutations
after codon 200 were more likely to be affected by visuo-
spatial impairment (8.0% vs. 2.0%, p Z 0.02) and spastic
paraparesis (33.7% vs. 7.8%, p < 0.001).Asian (Chinese, Japanese, and Korean) FAD and
ethnic differences
Table 5 summarizes the reported FAD cases in Chinese
families. There were a total of 18 Chinese families with 47
patients affected by FAD (mean age 44  6.6 years;
n Z 41). As much as 56% of the Chinese families harbored
novel mutations. Table 6 summarizes the reported FAD
cases in Asian families. There were a total of 77 Asian
families with 137 patients affected by FAD (mean age
45.0  7.9 years; n Z 123). As much as 42.9% of the Asian
families harbored novel mutations. The median duration of
disease was 11 years (IQR 8e13 years) and PSEN1 was the
most frequent mutation (71.5%). Asian patients with PSEN1
mutations had the earliest mean AOO (44  7.7 years,
p Z 0.008) and longest duration of disease (median 12
years; IQR 9e14 years, p Z 0.046; Table S3 in the supple-
mentary material online). We estimated the prevalence of
Table 2 Comparison of clinical characteristics of patients suffering from familial Alzheimer’s disease with mutations in PSEN1,
PSEN2, and APP.
Genotypes PSEN1 mutations PSEN2 mutations APP mutations APP duplication p
Mean age of onset (y) 43.3  8.6
(N Z 564)
58.1  9.5
(N Z 65)
47.6  7.1
(N Z 119)
51.5  5.3
(N Z 42)
<0.001 *
Female 57.7 54.5 65 35 0.018 **
Mean MMSE score at presentation 16  7.3
(N Z 120)
18  7.4
(N Z 11)
14  7.0
(N Z 22)
12  6.0
(N Z 14)
NS *
Mean age of death (y) 50.5  9.7
(N Z 226)
71.8  10.6
(N Z 17)
58  8.4
(N Z 48)
60.4  6.2
(N Z 27)
<0.001 *
Median years of clinical course before
death (IQR)
8 (5e11)
(N Z 239)
11 (10e15)
(N Z 17)
8 (6e14)
(N Z 52)
8 (5e13)
(N Z 28)
0.03 ***
Data are presented as or mean  SD unless otherwise indicated.
APP Z amyloid precursor protein; IQR Z interquartile range; MMSE Z Mini-Mental State Examination; NS Z not significant;
PSEN Z presenilin.
* One-way analysis of variance.
** Chi-square test (PSEN1 vs. PSEN2 vs. APP vs. APP duplication).
*** KruskaleWallis test.
Table 3 Initial presenting cognitive symptoms and atypical clinical features in FAD patients.
Initial presenting symptoms Overall PSEN1 PSEN2 APP APP duplications p *
Amnesia 379 (84) 271 (84.2) 29 (87.9) 67 (81.7) 12 (85.7) NS
Agnosia 28 (6.2) 18 (5.9) 2 (6.0) 5 (6.1) 3 (21.4) NS
Apraxia 76 (16.9) 47 (14.6) 8 (24.2) 15 (18.3) 6 (42.8) 0.03
Aphasia 130 (28.1) 102 (30.6) 7 (21.2) 17 (20.7) 4 (28.6) NS
Dyscalculia 54 (12) 37 (11.5) 4 (12.1) 13 (15.9) 0 NS
Disorientation 102 (22.7) 61 (19.0) 12 (36.3) 24 (29.3) 5 (35.7) 0.03
Apathy 58 (12.9) 40 (12.5) 7 (21.2) 10 (12.2) 1 (7.1) NS
Depression 63 (14.0) 44 (13.7) 9 (27.2) 10 (12.2) 0 NS
Aggression 20 (4.4) 9 (2.8) 3 (9.0) 8 (9.8) 0 0.02
Auditory hallucination 15 (3.3) 14 (4.3) 0 1 (1.2) 0 NS
Visual hallucination 19 (4.2) 15 (4.6) 3 (9.0) 1 (1.2) 0 NS
Visuospatial impairment 28 (6.2) 17 (5.3) 0 7 (8.5) 3 (21.4) NS
Delusion 22 (5.1) 12 (3.7) 4 (12.1) 5 (6.1) 1 (7.1) NS
Personality change 40 (8.9) 33 (10.3) 2 (6.1) 5 (6.1) 0 NS
Atypical clinical features
Parkinsonism 61 (13.3) 44 (13.4) 3 (9.1) 13 (15.9) 1 (7.1) NS
Seizures 135 (28.0) 101 (29.4) 5 (15.2) 13 (15.9) 16 (66.7) <0.001
Spastic paraparesis 77 (16.3) 76 (22.1) 1 (3.0) 0 0 <0.001
Myoclonus 126 (26.8) 107 (31.3) 3 (9.1) 14 (17.1) 2 (14.3) 0.003
Cerebellar sign 41 (9.1) 40 (12.5) 0 1 (1.2) 0 0.002
Data are presented as n (%).
APP Z amyloid precursor protein; FAD Z familial Alzheimer’s disease; NS Z not significant; PSEN Z presenilin.
* Chi-square test.
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data from Asian countries.95e97 The estimated prevalence
of FAD in China was 0.003 cases/100,000 population. The
estimated prevalence of FAD was 0.06 cases/100,000 pop-
ulation in Japan and 0.02 cases/100,000 population in South
Korea.
Clinical data from Asian FAD patients (including Chinese,
Japanese, and Korean patients) were compared with whites
(Europeans and non-African Americans) and summarized in
Tables S2 and S3 in the supplementary material online.
When compared with whites, Asian FAD patients had a
longer disease duration (median 11 years vs. 8 years,p Z 0.03). Those with PSEN1 mutations more frequently
presented with disorientation (31.8% vs. 17.8%, p Z 0.02)
and personality change (25.8% vs. 6.3%, p Z 0.01) but less
frequently had dysexecutive syndrome (1.5% vs. 11.5%,
p Z 0.01), seizures (16.7% vs. 31.9%, p Z 0.02), spastic
paraparesis (13.6% vs. 27.3%, p Z 0.02), myoclonus (10.6%
vs. 37.0%, p < 0.001), and cerebellar features (0% vs. 17.3%,
p < 0.001) along the clinical course; those with APP mu-
tations presented less frequently with aphasia (4.3% vs.
28.1%, p Z 0.02). There was no difference in the distribu-
tion of mutations (i.e., before or after codon 200) between
Asians and whites with PSEN1 mutations (p Z 0.98). We
Table 4 Comparison of clinical features between PSEN1
mutations before or after codon 200.
Clinical features Before codon
200
After codon
200
p *
Visuospatial
impairment
3 (2)
(N Z 148)
14 (8)
(N Z 173)
0.02
Seizures 58 (36.9)
(N Z 157)
43 (23.1)
(N Z 186)
0.01
Spastic paraparesis 12 (7.8)
(N Z 154)
64 (33.7)
(N Z 190)
<0.001
Myoclonus 67 (42.7)
(N Z 157)
40 (21.6)
(N Z 185)
<0.001
* Chi-square test.
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white FAD patients with p.Val717Ile APP and p.His163Arg
PSEN1 mutations, which showed no difference in clinical
characteristics (data not shown).Discussion
To the best of our knowledge, we have performed the most
comprehensive review of all the reported articles on FAD
patients published in the past 24 years. Such a review is
important because from the clinical point of view, accurate
description of the FAD cases is important for allowing early
detection of FAD and performing a good genetic counseling.
Most of the literatures on the FAD cases were in the form of
isolated case reports or case series and it is difficult for
clinicians to grasp certain basic fundamental clinical char-
acteristics including AOO, disease duration, initial clinical
manifestations, or development of atypical clinical fea-
tures along the clinical course. From the scientific point of
view, these monogenic mutations offer us a great oppor-
tunity to link the genotypic changes with the pathophysio-
logical and clinical manifestations to enhance our
knowledge of AD.Table 5 Summary of reported familial Alzheimer’s disease in C
Genotypes Overall PSEN1
Affected patients 47 (100) 29 (61
No. of families 18 (100) 12 (66
Mean age of onset (y) 44  6.6
(N Z 41)
44 
(N Z
Female 34 (81.0)
(N Z 42)
19 (79
(N Z
Median MMSE at presentation (IQR) 15 (10e18)
(N Z 16)
12 (4e
(N Z
Median years of clinical course
before death (IQR)
10.5 (7.3e14.3)
(N Z 12)
10.5 (
(N Z
Data are presented as n (%) unless otherwise indicated.
APP Z amyloid precursor protein; IQR Z interquartile range; M
PSEN Z presenilin.
* Independent sample t test (PSEN1 vs. APP).
** Chi-square test.
*** ManneWhitney test (PSEN1 vs. APP).The mean AOO and disease duration in all FAD patients
were similar to the findings in another systematic review
and meta-analysis (mean AOO 45.6  9.4 years vs. 46.3
years; mean disease duration 9.2  4.7 years vs. 9.7  5.1
years).4 Our findings of mean AOO for patients with PSEN1
and APP mutations were similar to the published systematic
review and meta-analysis (PSEN1: 43.3  8.6 years vs. 43.8
years; APP: 47.6  7.1 years vs. 49.7 years).4 Our findings of
mean AOO for patients with PSEN2 mutations were similar
to the other systematic review (58.1  9.5 years vs. 55.3
years).5 All these findings signify that our studied patients
were representative of the general FAD patients. We have
confirmed in our systematic review that patients with
PSEN1 mutations have the earliest AOO, whereas patients
with PSEN2 mutations have the oldest AOO and longest
disease duration.
With regard to the clinical features, up to 16% of the FAD
patients did not present with memory problem. Some
cognitive symptoms are gene specific. For example, we
found that APP duplications more commonly presented with
apraxia; PSEN2 mutations more commonly presented with
disorientation; and APP mutations more commonly pre-
sented with aggression. In addition, patients with PSEN1
mutations are likely to experience atypical clinical features
along their clinical course (including seizures, spastic par-
aparesis, myoclonus, and cerebellar signs). Clinicians
should be aware about these associations during the clinical
consultation. Such observations may also reflect the rela-
tionship between the underlying genes mutated and clinical
manifestations. Mutation position in PSEN1 can also result
in differences in clinical manifestations: patients with
mutations before codon 200 are more likely to suffer from
seizures and myoclonus along the clinical course, whereas
the reverse is true for visuospatial impairment and spastic
paraparesis. It has been found previously that cases with
mutations between codon 1 and 200 showed, in the frontal
cortex, many diffuse plaques, few cored plaques, and mild
or moderate amyloid angiopathy. While cases with muta-
tions occurring after codon 200 also showed many diffuse
plaques, the number and size of cored plaques werehinese families.
mutations PSEN2 mutations APP mutations p
.7) 2 (4.3) 16 (34.0) d
.7) 1 (5.6) 5 (27.8) d
6.2
24)
46  4.2 45  8.8
(N Z 16)
NS*
.2)
24)
2 (100)
(N Z 2)
13 (81.3)
(N Z 16)
NS **
19)
11)
17.5 (17e18)
(N Z 2)
14 (13e18)
(N Z 3)
NS ***
8.5e11.8)
4)
10.5 (9e12)
(N Z 2)
11 (5.8e15.3)
(N Z 6)
NS ***
MSE Z Mini-Mental State Examination; NS Z not significant;
Table 6 Clinical spectrum among different genotypes of FAD in Asian (Chinese, Korean, and Japanese) families.
Genotypes Overall PSEN1 mutations PSEN2 mutations APP mutations a p
No. of patients 137 (100) 98 (71.5) 2 (1.5) 37 (27.0) d
No. of families 77 (100) 56 (72.7) 1 (1.3) 20 (26.0) d
Mean age of onset (y) 45  7.9
(N Z 123)
44  7.7
(N Z 87)
46  4.2 49  7.6
(N Z 34)
0.008 *
Female 73 (68.2)
(N Z 107)
47 (63.5) 2 (100) 24 (77.4) NS **
Mean MMSE at presentation 15  7.5
(N Z 45)
15  8.2
(N Z 32)
18  0.7 14  6.0
(N Z 11)
NS *
Mean years of clinical course before death 11 (8e13)
(N Z 34)
12 (9e14)
(N Z 21)
11 (9e12) 7 (5e15)
(N Z 11)
0.046 ***
Data are presented as n (%).
APP Z amyloid precursor Protein; FAD Z familial Alzheimer’s disease; MMSE Z Mini-Mental State Examination; NS Z not significant;
PSEN Z presenilin.
a Including two families with two patients with APP duplication.
* Independent sample t test (PSEN1 vs. APP).
** Chi-square test (PSEN1 vs. APP).
*** ManneWhitney test (PSEN1 vs. APP).
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vessels severely affected by amyloid angiopathy.98 The
differences in clinical manifestations might be related to
these underlying differences in pathological changes.
To our knowledge, the presented review was the first
systematic review on Asian FAD. Asians account for only
11.7% of all FAD families in this review. In 2010, the number
of individuals with dementia in Asia was estimated to be
15.94 million and 60% of them were diagnosed with AD.
Based on estimates, there should be around 47,820 patients
with FAD.99 Based on these estimations, we believe that
many Asian FAD patients remain under-recognized due to
the lack of awareness. The comparison of clinical features
between Asian and white FAD patients with PSEN1 and APP
mutations indicated that there might be differences in
clinical characteristics between these patients. Thus, these
differences in clinical features must also be considered
when encountering potential Asian FAD patients. In addi-
tion, 42.9% of Asian families harbor new mutations. Diag-
nosing more FAD in Asians can potentially detect more
novel mutations, which can facilitate our understanding of
pathophysiology of AD. Asymptomatic FAD carriers can
serve as good candidates for disease-modifying treatment
trial. The Dominantly Inherited Alzheimer Network has
been established since 2008 in Western countries.100 By
increasing the awareness of FAD in Asian countries, perhaps
FAD families in Asia can form a similar network to facilitate
research on imaging, cerebrospinal fluid biomarkers, and
disease-modifying drug trials in FAD asymptomatic carriers
so that definitive treatment for sporadic AD will one day be
made possible.
There were limitations in this review. Approximately 42%
of the included FAD patients had analyzable clinical details.
The reason is that most of the articles mainly focused on
the biological effects of the mutations while reporting less
on the phenotypic information. In addition, novel muta-
tions are more likely to be published compared with known
mutations; therefore, our review may not be comprehen-
sive due to publication bias. There were significantheterogeneity of the purposes and methods among
different studies and case reports; additionally, the clinical
data were heterogeneous in quality; hence, there were
significant selection bias during the comparison of clinical
features of patients. In addition, there were significant
differences in the number of Asian and white FAD patients,
together with the missing clinical information, and thus,
our results should be interpreted with caution and treated
as a preliminary finding only. However, these results should
be confirmed in future studies with more reported Asian
FAD patients and once a large clinical database has been set
up. It was not possible to ascertain whether specific man-
ifestations were not reported because they were not
available in the clinical history or because there was no
information regarding their presence. Therefore, we
considered each symptom or sign as present or absent only
if their presence or absence were clearly stated, which may
affect our results. We have included in our review the
mutations considered as “possibly pathogenic” according to
Guerreiro et al7 as we wanted to perform an exhaustive
review on all the available FAD patients. However, we
might have included noncausative or rare normal variants
as well. The disease duration was unable to reflect the
“true” quality of life experienced by the FAD patients.Conclusion
In conclusion, certain clinical characteristics are gene
specific: PSEN1 mutations have the earliest AOO and were
more frequently affected by atypical clinical features along
the clinical course; PSEN2 mutations have a delayed AOO
with the longest disease duration and presented more
frequently with disorientation; APP mutations presented
more frequently with aggression and APP duplication pre-
sented more frequently with apraxia. Because 42.9% of the
mutations reported are novel, the mutation spectrum and
clinical features in Asian FAD families could be different
from whites patients.
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Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jfma.2015.08.004.References
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